计算溶液所需的质量、体积或浓度。
| 活性类型 | 活性值-log(M) | 作用机制 | 期刊 | 参考文献(PubMed IDs) |
|---|
Moligand™ 级 提供 ≥98% 纯度,适用于对基线干扰要求严格的色谱和分析工作流程。
-20°C储存,充氩。超低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
CGP77675 is an orally active and potent inhibitor of Src family kinases. CGP77675 inhibits phosphorylation of peptide substrates and autophosphorylation of purified Src ( IC 50 s of 5-20 and 40 nM, respectively), and also inhibits Src , EGFR , KDR, v-Abl, and Lck with IC 50 s of 5-20, 40, 20, 150, 1000, 310, and 290 nM, respectively. Anticancer activity
In Vitro
CGP77675 dose dependently inhibits phosphorylation of poly-Glu-Tyr with an IC 50 value of 5.5 nM, and of the optimal Src substrate (OSS) peptide with an IC 50 value of 16.7 nM. These IC 50 values are similar to the value obtained with chicken Src (20 nM). CGP77675 inhibits the parathyroid hormone-induced bone resorption in rat fetal long bone cultures with an IC 50 of 0.8 μM. CGP77675 (0.04-10 μM; 2 hours) potently inhibits tyrosine phosphorylation of the Src substrates Fak and paxillin, but has much less effect on Src (IC 50 values 0.2, 0.5, and 5.7μM) in IC8.1 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: MC3T3-E1 cells Concentration: 0.2, 1, and 5 μM Incubation Time: 3 days Result: Did not influence cell viability for up to 3 days of treatment. Western Blot AnalysisCell Line: Src-overexpressing IC8.1 cells Concentration: 0.04, 0.2, 1, 5, and 10 μM Incubation Time: 2 hours Result: Dose dependently inhibited phosphorylation of Fak and paxillin, but not of Src.
In Vivo
CGP77675 (1, 5, and 25 mg/kg; injected s.c.; twice a day) inhibits IL-1β-induced hypercalcemia in Mice . CGP77675 (10 and 50 mg/kg; administered orally; twice a day for 6 weeks) partially prevents bone loss and rescues bone microarchitectural features in young ovx rats . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male mice (Tif:MAGf; Novartis Animal Farm) of 25-30 g body Dosage: 1, 5, and 25 mg/kg Administration: Injected s.c.; twice a day Result: Prevented IL-1β-induced hypercalcemia in mice without affecting serum amyloid protein levels. Animal Model: Eight-week-old (175-209 g) female rats of the Sprague-Dawley-derived strain Tif:RAlf Dosage: 10 and 50 mg/kg Administration: Administered orally; twice a day for 6 weeks Result: Partly prevented bone loss.
Form:Solid
IC50& Target:IC50: 0.02 μM (Src), 0.15 μM (EGFR), 1.0 μM (KDR), 0.31 μM (v-Abl), 0.29 μM (Lck)
分类树(Taxonomy Tree)
| 界(kingdom) | 有机化合物 |
|---|---|
| 超类(Superclass) | 有机杂环化合物 |
| 类(Class) | 吡咯类 |
| 亚类(Subclass) | 取代吡咯 |
| 中间层级节点(Intermediate Tree Nodes) | 暂无 |
| 直接上位类(Direct Parent) | 苯基吡咯 |
| 其他上位类(Alternative Parents) | 吡咯并[2,3-d]嘧啶 苯乙胺 苯氧基化合物 甲氧基苯 茴香醚 烷基芳基醚 氨基嘧啶及其衍生物 芳烷基胺 哌啶类 咪唑内酰胺类 杂芳族化合物 三烷基胺 仲醇 氮杂环化合物 碳氢化合物衍生物 伯胺 |
| 分子骨架(Molecular Framework) | 芳香族杂多环化合物 |
| 取代基(Substituents) | 1-苯基吡咯 - 3-苯基吡咯 - 羟基苯甲酸酯 - 芳基醚 - 氨基酸 - 氨基吡啶 - 茴香醚 - 芳烷基胺 - 芳香族杂多环化合物 - 氮杂环 - 苯基化合物 - 乙醚 - 杂芳香族化合物 - 烃衍生物 - 咪唑内酰胺 - 甲氧基苯 - 单环苯基基团 - 有机硝基化合物 - 有机氧化合物 - 有机氮化合物 - 有机氧化合物 - 苯乙胺 - 苯酚醚 - 苯氧基化合物 - 哌嗪 - 初级胺 - 嘧啶 - 吡咯并[2,3-d]嘧啶 - 吡咯吡啶 - 醛基 - 三元脂肪胺 - 三芳基胺 |
| 描述(Description) | 该化合物属于苯并吡咯类有机化合物。这类多环芳烃化合物通过碳碳键或氰基键将苯环与吡咯环相连。 |
| 外部描述符(External Descriptors) | 暂无 |
| 作用机制 | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | 参考文献 |
|---|